Therapix Biosciences Updates Regarding TASE Delisting
Therapix Biosciences Updates Regarding TASE Delisting |
[27-June-2018] |
TEL AVIV, Israel, June 27, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, provides updates and dates in connection with the previous announcement made by Therapix Biosciences Ltd. ("Therapix" or the "Company") regarding the Company's intention to voluntarily delist its ordinary shares, NIS 0.1 par value each (the "Shares") solely from the Tel Aviv Stock Exchange Ltd. ("TASE"), the Company hereby updates the following: In coordination with the TASE, the Shares will be delisted from the TASE on August 9, 2018 ("Delisting Date"), and until the Delisting Date, Therapix's Shares will continue to be traded on the TASE. The last trading day in which the Shares are to be traded on TASE will be August 7, 2018. The Company's American Depositary Shares ("ADSs"), each representing forty (40) of the Company's Shares, shall continue to be traded on the Nasdaq Capital Market (the "Nasdaq"). Shareholders who are interested in continuing to hold or trade the Company's Shares on the Nasdaq should notify their bank or broker as soon as possible and request to convert their Shares to ADSs. The Company will bear the costs and commissions associated with the conversion of the Shares to ADSs charged by the banks and brokers for all shareholders who convert their Shares on or before August 7, 2018. Every forty (40) Shares shall be converted to one (1) ADS. The Company urges all holders of Shares that are traded on the TASE to convert their Shares into ADSs at the earliest. Holders of the Company's Shares are encouraged to contact their banks or brokers as soon as possible with any questions about the conversion process. About Therapix Biosciences: Forward Looking Statements Investor Contact
View original content:http://www.prnewswire.com/news-releases/therapix-biosciences-updates-regarding-tase-delisting-300673112.html SOURCE Therapix Biosciences Ltd. | ||
Company Codes: NASDAQ-SMALL:TRPX, OTC-QB:TRPX, TelAviv:TRPX |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}